Literature DB >> 6767674

Sarcocystosis in cattle in Kentucky.

R C Giles, R Tramontin, W L Kadel, K Whitaker, D Miksch, D W Bryant, R Fayer.   

Abstract

Sarcocystosis was diagnosed in 41 eighteen-month-old heifers and steers. Clinical signs included anorexia, severe weight loss, nervousness, hypersalivation, lameness, and hair loss on the extremities. Hair loss was noticed especially at the end of the tail, where there was complete loss of the switch, giving the animals a "rat-tail" appearance. Consistent gross changes observed at necropsy of four affected animals included generalized lymphadenopathy, erosions and ulcerations in the oral cavity and esophagus, and severe laminitis. Microscopically, young cysts of Sarcocystis sp were disseminated in the heart, skeletal muscle, and brain. Ultrastructural examination indicated that the cysts were young because they contained metrocytes. Affected animals had moderate to severe nonsuppurative myocarditis and myositis, with focal degeneration of myofibers and infiltration by macrophages, lymphocytes, and plasma cells. Indirect hemagglutination of sera from 19 animals revealed a mean antibody titer of 1:24,000 against Sarcocystis bovicanis antigen. Epidemiologic investigation incriminated resident farm dogs that had been housed in a farm hayloft as the source of infection. Hay contaminated with sporocysts in dog feces was thought to have been fed to the heifers and steers.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6767674

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  2 in total

1.  Serologic profiles for Sarcocystis sp. and Neospora caninum and productive performance in naturally infected beef calves.

Authors:  Gastón Moré; Diana Bacigalupe; Walter Basso; Magdalena Rambeaud; Maria C Venturini; Lucila Venturini
Journal:  Parasitol Res       Date:  2010-01-26       Impact factor: 2.289

2.  Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma.

Authors:  T Noda; H Nagano; I Takemasa; S Yoshioka; M Murakami; H Wada; S Kobayashi; S Marubashi; Y Takeda; K Dono; K Umeshita; N Matsuura; K Matsubara; Y Doki; M Mori; M Monden
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.